

04 Feb 2020 |

# Podcast: Key Takeaways From J.P. Morgan

by **Jessica Merrill**

Scrip journalists join Datamonitor Healthcare's Mike Ramirez to share their impressions from the 2020 J.P. Morgan conference in San Francisco. Talking points range from M&A to the drug pricing debate, via individual company strategies, the impending US election and more.

In conversation with [Datamonitor Healthcare](#) analyst Mike Ramirez, Scrip journalists Jessica Merrill and Andrew McConaghie share their thoughts and observations from the biopharma industry's unofficial annual kick-off event, the J.P. Morgan Healthcare conference.

[Click here to explore this interactive content online](#) ✎

Datamonitor Healthcare

*Topics covered in this podcast include:*

- Intro/general discussion of the meeting (0:00-4:17)
- Focus on execution at this year's meeting (4:17-6:14)
- Companies that may be poised to make M&A deals in the near future (6:14-9:05)
- Potential reasons behind lack of M&A, including uncertainty around the US election, valuation expectations (9:05-16:49)
- Discussion on drug pricing regulation (16:49-23:31)

- Sessions of particular interest (23:31-34:24)

For additional Informa Pharma Intelligence podcasts, visit [soundcloud.com/pharmaintelligence](https://soundcloud.com/pharmaintelligence)